TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01072656

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation for Thalamic Pain Syndrome
Description: Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation for Thalamic Pain Syndrome
Description: Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
Study: NCT00519571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImplantLock device
Description: dental implant
Study: NCT01951976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Classes
Description: Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
Study: NCT03507270

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FABP
Description: Assessment of changes in FABP concentrations
Study: NCT03108742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSORB
Description: dermal stapler for skin closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic intradermal suture
Description: intradermal suture for skin closure
Study: NCT01485185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin lower dose
Description: Repeat, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Repeat, oral dose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Dop)
Description: Placebo to donepezil, Repeat, oral dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Gaba)
Description: Placebo to gabapentin, Repeat, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin higher dose
Description: Repeat, oral dose
Study: NCT04312815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SM03
Description: SM03: 600 mg intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM03
Description: SM03: 600 mg intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 600 mg intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Methotrexate: 7.5-20 mg/wk oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Methotrexate: 7.5-20 mg/wk oral
Study: NCT00864539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified milk
Description: daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plain milk
Description: daily intake of 200 ml plain milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified orange juice
Description: daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plain orange juice
Description: daily intake of 250 ml plain orange juice
Study: NCT01794663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion for 1 hour at start of transplant procedure
Study: NCT01932372

Intervention type: DRUG
Intervention: Tofacitinib (Xeljanz)
Description: 5 mg Tablet BID

Intervention type: DRUG
Intervention: Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
Description: Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
Study: NCT03661307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04382586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 320 mg (4 x 80 mg) capsules administered orally once daily
Study: NCT02662283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reh-acteoside
Description: Oral take and reh-acteoside (0.4g bid) for 8 weeks
Study: NCT01189487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampicillin sodium/sulbactam sodium
Description: ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
Study: NCT04304040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized monoclonal antibody MIL62 injection
Description: Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
Study: NCT00517556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCOCP
Description: (CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional OCP
Description: (traditional OCP) (21 active days/7 inactive days) treatment regimen
Study: NCT04113863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole 1mg
Description: Anastrozole will be administered orally at the dosage of 1 mg/die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1mg
Description: Anastrozole will be administered orally at the dosage of 1 mg/die.
Study: NCT01844856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Study: NCT04382586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Supportive care treatment was selected and administered as deemed appropriate by the study investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Supportive care treatment was selected and administered as deemed appropriate by the study investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match zanubrutinib
Study: NCT04532294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB DXP593
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB DXP593
Description: Administered intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match BGB-DXP593
Study: NCT04116411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir Tablets
Description: Valganciclovir treatment of glioblastoma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide 120 mg
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide 120 mg
Description: Chemotherapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy 60 Gy
Description: Radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 60 Gy
Description: Radiation therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo treatment of glioblastoma
Study: NCT01636336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
Study: NCT04000607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APTURE transcatheter shunt
Description: Transcatheter treatment of symptomatic left heart failure patients
Study: NCT00420927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
Study: NCT03032146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
Study: NCT04383795

Intervention type: DRUG
Intervention: Antithyroid Drug
Description: Administration of antithyroid Drug for 6 months
Study: NCT00320411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib 1500mg QD
Study: NCT01947205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen trometamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: suction curettage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: suction curettage
Study: NCT03136172

Intervention type: DEVICE
Intervention: NIRS (near Infra-red spectroscopy)
Description: 1. NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~2. Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~3. Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)
Study: NCT01947205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without drug
Study: NCT02332850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV
Study: NCT00864539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium-vitamin D supplement
Description: daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily placebo
Study: NCT04283773

Intervention type: COMBINATION_PRODUCT
Intervention: p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)
Description: Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
Study: NCT02332850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study: NCT03085420

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
Study: NCT00700960

Intervention type: DRUG
Intervention: insulin detemir
Description: initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
Study: NCT00449774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine IR tablets
Description: Lamotrigine IR tablets will be available in dose strength of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine ODT tablets
Description: Lamotrigine ODT tablets will be available in dose strength of 200 mg.
Study: NCT02902198

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tap water 200ml
Study: NCT00449774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine ODT tablets
Description: Lamotrigine ODT tablets will be available in dose strength of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine ODT tablets
Description: Lamotrigine ODT tablets will be available in dose strength of 200 mg.
Study: NCT02902198

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tap water 200ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 25g Glucose in 200ml tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 25g Glucose in 200ml tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Monosodium glutamate
Description: 1g monosodium glutamate in 200ml tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Monosodium glutamate
Description: 1g monosodium glutamate in 200ml tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: 17mg quinine in 200ml tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: 17mg quinine in 200ml tap water
Study: NCT05145530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: selective anterior cervical discectomy and fusion (ACDF)
Description: selective anterior cervical discectomy and fusion (ACDF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNRB+ selective anterior cervical discectomy and fusion (ACDF)
Description: US-guided selective nerve root block (SNRB) + selective anterior cervical discectomy and fusion (ACDF)
Study: NCT03764501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Image fusion system
Description: Image fusion system for the 3D preoperative planning
Study: NCT00861276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Spray Nicotine Substitute (Experimental)
Description: During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray Nicotine Substitute (ad libitum)
Description: In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
Study: NCT05825521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging
Study: NCT00977249

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: support and visits
Description: visits at weeks 0,2,4,6,9 and 12 and 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: support and visits
Description: visits at weeks 0,2,4,6,9 and 12 and 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04325217

Intervention type: DRUG
Intervention: Nintedanib
Description: Capsules
Study: NCT01185600

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Washed RBC
Description: There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
Study: NCT04283773

Intervention type: COMBINATION_PRODUCT
Intervention: p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)
Description: Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).

Intervention type: COMBINATION_PRODUCT
Intervention: Ki67 antibody (DAKO) for malignant cases only
Description: Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
Study: NCT00693563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled Telephone Intervention
Description: Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
Study: NCT06049628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIFA 11+ exercise program
Description: FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine program
Description: This program consists of jogging, and stretching exercises.
Study: NCT03042494

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Isocaloric food without the test prebiotic.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
Study: NCT02482415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-educational
Study: NCT01097733

Intervention type: OTHER
Intervention: Randomization of Pre-knowledge of CT coronary venography
Study: NCT04990999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Root Extraction
Description: a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic extractions using periotomes followed by conventional forceps
Description: a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.